RiboNova Inc.
RiboNova Inc. is dedicated to helping patients suffering from serious rare diseases by discovering and developing novel medicines to treat their conditions. The company focuses on mitochondrial disease, a devastating rare disease affecting about 75,000 people in the United States. Their lead product candidate, R007, is a Phase-2 ready small molecule for the treatment of inherited mitochondrial disease.
Industries
biotechnology
medical
pharmaceutical
Nr. of Employees
small (1-50)
RiboNova Inc.
Wynnewood, Pennsylvania, United States, North America
Products
Lead small-molecule clinical candidate (Phase-2 ready) for inherited mitochondrial disease
A small-molecule therapeutic candidate advanced to Phase-2 readiness for the treatment of inherited mitochondrial disease.
Lead small-molecule clinical candidate (Phase-2 ready) for inherited mitochondrial disease
A small-molecule therapeutic candidate advanced to Phase-2 readiness for the treatment of inherited mitochondrial disease.
Expertise Areas
- Rare disease drug development
- Mitochondrial disease therapeutics
- tRNA-targeted therapeutics
- Small-molecule drug development
Key Technologies
- Small-molecule therapeutics
- tRNA-targeted discovery methods
- Mitochondrial-targeting therapeutic approaches
- Drug development pipeline management